Sentences with phrase «trial study with»

We performed a randomized clinical trial study with long - term follow up.

They performed a randomized clinical trial study with long - term follow up.

Not exact matches

While the new mid-stage study results from DNDi were impressive (they showed cure rates of 96 % to 97 % even for the sickest patients and those with liver scarring), more late - stage trials will be necessary before the drug is available on a large scale in the developing world.

The Chinese government financed nationwide studies into cockroaches» medical value that, after more than two decades of laboratory investigation and clinical trials, had discovered or confirmed dozens of disease - fighting proteins and biochemical compounds with huge potential value in medicine.

After that, Watson will take assist by providing both physician and patient with a report that includes the most relevant drug trial and academic studies for their specific conditions.

Currently in the U.K., he will go back to Privateer's headquarters in Seattle, then visit Tilray's 60,000 - square foot facilities in British Columbia, Canada, then to Australia, where Tilray has an import license to send marijuana for a clinical trial with a chemotherapy - induced nausea and vomiting study with the University of Sydney, the government of New South Wales and the country's largest cancer hospital.

Actual results and the timing of events could differ materially from those anticipated in the forward - looking statements due to these risks and uncertainties as well as other factors, which include, without limitation: the uncertain timing of, and risks relating to, the executive search process; risks related to the potential failure of eptinezumab to demonstrate safety and efficacy in clinical testing; Alder's ability to conduct clinical trials and studies of eptinezumab sufficient to achieve a positive completion; the availability of data at the expected times; the clinical, therapeutic and commercial value of eptinezumab; risks and uncertainties related to regulatory application, review and approval processes and Alder's compliance with applicable legal and regulatory requirements; risks and uncertainties relating to the manufacture of eptinezumab; Alder's ability to obtain and protect intellectual property rights, and operate without infringing on the intellectual property rights of others; the uncertain timing and level of expenses associated with Alder's development and commercialization activities; the sufficiency of Alder's capital and other resources; market competition; changes in economic and business conditions; and other factors discussed under the caption «Risk Factors» in Alder's Annual Report on Form 10 - K for the fiscal year ended December 31, 2017, which was filed with the Securities and Exchange Commission (SEC) on February 26, 2018, and is available on the SEC's website at www.sec.gov.

Swiss drug giant Novartis is partnering with California - based Science 37 in an effort to expand clinical study participation (while lowering the costs of such studies) through «virtual» trials.

In a late - stage study, Aimmune, a biotech immunotherapy allergy treatment taken via pill, found that of the roughly 500 kids with peanut allergies between the ages of 4 - 17 who were part of the trial, 67 % of those who received the treatment were able to tolerate 600 milligrams of peanut protein (about two to four peanuts) after about a year of treatment, while only 4 % of those who got the placebo could tolerate that dose of peanut protein.

Studies — including at least one clinical trial with 100 participants — have found that this diet can significantly alter signs of disease, reduce weight and body fat, lower blood pressure, decrease levels of biomarkers associated with cancer, and improve blood - sugar levels.

As other boards use HP as a case study and learn from its trials, perhaps it's time for HP to also re-examine the board's level of involvement with the company's strategy — before the company presents their ideas to the public.

NOVARTIS PARTNERS WITH SCIENCE 37 TO DEVELOP «VIRTUAL TRIALS»: Swiss drugmaker Novartis announced plans to work with virtual clinical trial company Science 37 to develop «remote trial» technology that uses video conferencing to lower the barrier of entry for recruiting study participants, according to ReutWITH SCIENCE 37 TO DEVELOP «VIRTUAL TRIALS»: Swiss drugmaker Novartis announced plans to work with virtual clinical trial company Science 37 to develop «remote trial» technology that uses video conferencing to lower the barrier of entry for recruiting study participants, according to Reutwith virtual clinical trial company Science 37 to develop «remote trial» technology that uses video conferencing to lower the barrier of entry for recruiting study participants, according to Reuters.

These risks and uncertainties include: Gilead's ability to achieve its anticipated full year 2018 financial results; Gilead's ability to sustain growth in revenues for its antiviral and other programs; the risk that private and public payers may be reluctant to provide, or continue to provide, coverage or reimbursement for new products, including Vosevi, Yescarta, Epclusa, Harvoni, Genvoya, Odefsey, Descovy, Biktarvy and Vemlidy ®; austerity measures in European countries that may increase the amount of discount required on Gilead's products; an increase in discounts, chargebacks and rebates due to ongoing contracts and future negotiations with commercial and government payers; a larger than anticipated shift in payer mix to more highly discounted payer segments and geographic regions and decreases in treatment duration; availability of funding for state AIDS Drug Assistance Programs (ADAPs); continued fluctuations in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead's earnings; market share and price erosion caused by the introduction of generic versions of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect of lowering prices or reducing the number of insured patients; the possibility of unfavorable results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials in its currently anticipated timeframes; the levels of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits of the Sangamo partnership; Gilead's ability to submit new drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (the SEC).

Take a much - trumpeted 2014 study out of MIT, in which research subjects underwent work trials with both human and robots in charge and found they preferred being managed by the machines.

The company's leading program, a differentiated PPAR gamma agonist (MIN - 102) that has multiple CNS indications, has successfully completed a phase 1 clinical trial and is ready to move into a phase 2/3 study with adult AMN patients.

While Tecentriq's results in Imvigor211 were consistent with its previous study, Roche said, patients getting chemotherapy in the latest trial survived longer than anticipated.

Juno is developing its immunotherapy product candidate, JCAR017, which is in a Phase I trial, studying patients with B - cell Non-Hodgkin Lymphoma [NHL].

Current studies of Jesus» trial are much concerned with this fact, seeming sometimes as anxious to blame the Romans as the evangelists were to blame the Jews.

I cant praise God enough for the internet we cant be ignorant these if we want to learn anything all we have to do is to jump on the internet for answers since I have accepted Jesus as my personal savior thirty five years ago i cant stop myself to share my experience with people but since i lost my husband through a tragic accident my life took a different turn my savior became more personal and real to me i give myself full to the lord and the result of that people stat asking me for bible study which i have never done in my life so I decided to search the net and i came across your website which put the whole gospel in a simple way and i am going to use it for my first bible study and see how the holy spirit will lead from there.I came to the conclusion that our trials is a blessing in disguise and i praise God for it.keep up the good work God bless Martina keep me in prayer please

Another more recent study assessed the efficiency of collagen peptides in a randomized, double blind, controlled multicenter trial, in which 250 subjects with primary osteoarthritis of the knee were given 10g of collagen peptides daily.

Improved postharvest practices: A recent research study undertaken by WFLO with funding by the Bill & Melinda Gates Foundation provides an great assortment of data on the results of 12 past projects, postharvest losses % for 26 crops, a description of the value chain for 30 crops in 4 countries (Rwanda, Benin, Ghana and India) and 21 field trials of postharvest technologies suitable for helping small farmers reduce losses and improve their incomes.

The result of the study showed that a significant amount more women in the study group went into labor when compared with the control group in each of the three trials.

As with neurobehavior, effects on breastfeeding are poorly studied, and more recent randomized controlled trials comparing exposure to epidural and opiate drugs are especially misleading because opiates have a well - recognized negative effect on early breastfeeding behavior and success.103 — 107

Another problem for randomized controlled trial with hydrotherapy is the inability to «blind» the study.

Although not directly comparable, our findings are in broad agreement with those from routine data in Scotland that have indicated a positive association between Baby Friendly accreditation, but not certification, and breastfeeding at 1 week of age.17 Our findings reinforce those of Coutinho and colleagues who reported that high exclusive breastfeeding rates achieved in Brazilian hospitals implementing staff training with the course content of the Baby Friendly Hospital Initiative were short - lived and not sustained at home unless implemented in combination with post-natal home visits.35 Similarly in Italy, training of staff with an adapted version of the Baby Friendly course content resulted in high breastfeeding rates at discharge, with a rapid decrease in the days after leaving hospital.36 In contrast, a cluster randomized trial in Belarus (PROBIT) found an association between an intervention modelled on the Baby Friendly Initiative with an increased duration of breastfeeding37 an association also reported from an observational study in Germany.38 Mothers in Belarus stay in hospital post-partum for 6 — 7 days, and in Germany for 5 days, with post-natal support likely to be particularly important in countries where mothers stay in the hospital for a shorter time, with early discharge likely to limit the influence of a hospital - based intervention.

Our study illustrates that a randomized intervention trial with good socioeconomic information can help assess interventions designed to improve population health not only by examining the intervention effects on primary outcomes but also by evaluating the intervention's impact on socioeconomic inequalities.

One randomized controlled trial comparing home - visited families with control participants who received other community services found a statistically significant difference in mean depressive symptoms at two years post-enrollment, but this contrast was nonsignificant at three years post - enrollment.15 A second study of Early Head Start found no differences in depressive symptoms between intervention and control group participants post-intervention, although a difference was detected at a longer - term follow - up prior to children's enrollment in kindergarten.10 Other randomized controlled trial studies have not found effects of home visitation on maternal depressive symptoms.12, 16,17

A series of randomized control trials of a nurse home visitation program show a range of positive effects on maternal health, including decreases in prenatal cigarette smoking, fewer hypertensive disorders in pregnancy, and fewer closely spaced subsequent pregnancies., A randomized control study of another program that works with a particularly high - risk population found that participant mothers showed significantly lower depressive symptoms than those in the control group and were less likely to report feeling stressed a year after participation.

The objective of the current study was to systematically review randomised controlled trials of parenting programmes for the treatment of children with conduct problems.

Out of the 10 included studies (a total of 5787 women, including 512 women interviewed as part of a cluster randomised trial), only two studies gathered data for multiples separately and were able to provide us with the data (Paul 2012; Reeder 2014, a total of 42 women with multiples).

Trials recruited 5787 women (this included 512 women interviewed as part of a cluster randomised trial); of these, data were available from two studies for 42 women with twins or higher order multiples.

The difference in the average treatment effect in overall fetal loss and neonatal death across included trials between women allocated to midwife - led continuity models of care and women allocated to other models has an average risk ratio (RR) of 0.84, with 95 % confidence interval (CI) 0.71 to 0.99 (participants = 17561; studies = 13).

However, the results of observational studies from developing countries are consistent with the findings of the two Honduran trials, particularly with respect to growth.

The difference in the average treatment effect in all fetal loss before and after 24 weeks plus neonatal death across included trials between women allocated to midwife - led continuity models of care and women allocated to other models has an average risk ratio (RR) of 0.84, with 95 % confidence interval (CI) 0.71 to 0.99 (participants = 17561; studies = 13).

The results of this trial stress the importance of providing premature neonates with raw milk from their own mother,» the study concludes.

All study participants gave written informed consent and the study was approved by the Monash University Human Research Ethics Committee (approval number CF12 / 0348 -2012000146), and the trial registered with the Australia and New Zealand Clinical Trial Registry (registration number 12611000468trial registered with the Australia and New Zealand Clinical Trial Registry (registration number 12611000468Trial Registry (registration number 12611000468921).

The PhD course focuses on various aspects of human (donor) milk, with as main study a randomized clinical trial towards the effects of human donor milk in very low birth weight infants (the Early Nutrition Ststudy a randomized clinical trial towards the effects of human donor milk in very low birth weight infants (the Early Nutrition StudyStudy).

This study is a randomized clinical trial (RCT) with 50 mother / infant pairs in the intervention arm, 50 in one control group and 25 in a third control group.

DF and K - TT advised on the study design, coordinated the study, liaised with participants, entered data, and monitored the trial.

We conducted our study in conjunction with the clinical trials and epidemiology research unit, which is an independent organisation funded by the National Medical Research Council.

A randomised trial in Brazil that compared a hospital based protocol (similar to the baby friendly hospital initiative) with another incorporating intensive home visits, however, found that while the protocol achieved high rates of exclusive breast feeding in hospital, the rates fell rapidly thereafter.27 These findings were confirmed in the UK by the millennium cohort study, 5 and the authors recommended that the baby friendly hospital initiative as a strategy for promotion of breast feeding should be reassessed and that other strategies are required to support mothers in the UK to breast feed for the recommended duration.5 27 Although combined antenatal education and postnatal support is ideal, this may be limited by economic or time resources.

Breast size increment during pregnancy and breastfeeding in mothers with polycystic ovarian syndrome: A follow - up study of a randomized controlled trial on metformin versus placebo.

«A number of observational studies and randomized trials, however, showed that routine episiotomy is associated with an increased incident of anal sphincter and rectal tears,» write the authors of Williams Obstetrics (23rd edition, p. 401, their emphasis), including a four to sixfold risk of fecal or flatus incontinence.

«This is the largest randomized trial of any behavioral intervention in children with autism spectrum disorder, and it shows that parent training works,» notes Lawrence Scahill, MSN, PhD, professor of pediatrics at Marcus and Emory School of Medicine, who directed the study.

So the review is based on far more studies than 2 with 11 people... it's just that is all of the * randomized * trials that were included.

There has been slight improvement in study reporting or quality, with 44 out of the 73 trials that contributed data (60 %) reporting an approach to allocation concealment that we considered to be at low risk of bias compared to 26 of the 52 trials (50 %) in the previous review (Renfrew 2012b).

The Effect of Skin - to - Skin Contact (Kangaroo Care) Shortly After Birth on the Neurobehavioral Responses of the Term Newborn: A Randomized, Controlled Trial Sari Goldstein Ferber and Imad R. Makhoul Pediatrics 2004; 113; 858 - 865 - DOI: 10.1542 / peds.113.4.858 This information is current as of March 25, 2007 The original version of this article, along with updated information and services, is located at: http://www.pediatrics.org/cgi/content/full/113/4/858 Background: The method of skin - to - skin contact (kangaroo care [KC]-RRB- has shown physiologic, cognitive, and emotional gains for preterm infants; however, KC has not been studied adequately in term newborns.

Declan Devane is a co-author in one of the included trials in this review (Begley 2011) Jane Sandall was and is principal investigator for two studies evaluating models of midwife - led continuity of care (Sandall 2001), and co-investigator on the «Birthplace in England Research Programme», an integrated programme of research designed to compare outcomes of births for women planned at home, in different types of midwifery units, and in hospital units with obstetric services.

The bill would make it mandatory for researchers to publish all information from cancer clinical trials, with the goal being to get more researchers to work together and bring down the number of duplicative studies.

'» (Translate is planning human trials with repeated doses of its own mRNA drug for both cystic fibrosis and a rare metabolic disorder called ornithine transcarbamylase deficiency in 2018, but it has not yet published animal studies with repeat dosing.)